Skip to main content
SpringerLink
Log in

Hematopoietic Growth Factors in Acute Leukemia

  • Chapter
Clinical Applications of Cytokines and Growth Factors

Part of the book series: Developments in Oncology ((DION,volume 80))

  • 111 Accesses

Abstract

The clinical use of hematopoietic growth factors (HGFs) in the acute leukemias has been associated both with great promise and significant pitfalls. The myeloid growth factors offered the potential to decrease complications of the highly myelosuppressive chemotherapy required to successfully treat acute leukemias. However, because the HGFs were shown to stimulate proliferation of myeloblasts 1, these agents came relatively late to be tested in clinical trials of supportive care in acute myeloid leukemias. Once both GM-CSF and G-CSF were shown not to possess clinically apparent leukemogenic activity, large randomized trials were conducted with generally positive, but not dramatically beneficial results. The very ability of the HGFs to interact with leukemia cells could, by inducing DNA synthesis, sensitize the cells to the cytotoxic effects of cell-cycle active chemotherapy 2. This so-called priming strategy has been explored in a preliminary fashion, but with generally disappointing results. The challenge ahead is to develop better ways to use existing HGFs and to integrate newer agents in this category into effective clinical strategies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Lowenberg B, Touw I: Hematopoietic Growth Factors and their receptors in acute leukemia. Blood 81:281–292, 1993

    PubMed  CAS  Google Scholar 

  2. Tafuri A, Andreef M: Kinetic rationale for cytokine-induced treatment of myeloblastic leukemia followed by cycle-specific chemotherapy in vitro. Leukemia 4:826–834, 1990

    PubMed  CAS  Google Scholar 

  3. Mayer RJ, Davis RB, Schiffer CA, et al: Intesive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 331:896–903, 1994

    Article  PubMed  CAS  Google Scholar 

  4. Stone RM, Mayer RJ: The approach to the elderly patient with acute myeloid leukemia. Hematol Oncol Clin North Am 7: 65–79, 1993

    PubMed  CAS  Google Scholar 

  5. Buchner T, Hiddeman W, Koenigsman M, et al: Human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse. Blood 78:1190–1197, 1991

    PubMed  CAS  Google Scholar 

  6. Estey E, Dixon D, Kantarjian H: Treatment of poor-prognosis newly diagnosed acute myeloid leukemia with ara-C and recombinant human granulocyte-macrophage colony-stimulating factor. Blood 75: 1766–1769, 1990

    PubMed  CAS  Google Scholar 

  7. Rowe J, Andersen J, Mazza, et al: A randomized placebo-controlled phase II study of (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the eastern cooperative oncology group (E1490). Blood 86: 457–462, 1995

    PubMed  CAS  Google Scholar 

  8. Stone R, Berg D, George S, et al: Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogeneous leukemia. N Engl J Med 332: 1671–1677, 1995

    Article  PubMed  CAS  Google Scholar 

  9. Ohno R, Tomonaga M, Kobayashi T et al: Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N Engl J Med 323: 871–876, 1990

    Article  PubMed  CAS  Google Scholar 

  10. Dombret H, Chastang C, Fenaux P, et al: A controlled study of recombinant human granulocyte-stimulating factor in elderly patients after treatment for acute myelogeneous leukemia. N Engl J of Med 332 1678–1683, 1995

    Article  CAS  Google Scholar 

  11. Godwin J, Kopecky K, Head D, et al: A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a southwest oncology group (9031). Blood 91: 3607–3615, 1998

    PubMed  CAS  Google Scholar 

  12. Heil G, Hoelzer D, Sanz et al: A randomized, double-blind, placebo-controlled, phase II study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. Blood 90: 4710–4718, 1997

    PubMed  CAS  Google Scholar 

  13. Moore J, Dodge R, Amrein P, et al: Granulocyte-colony stimulating factor (fligrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: cancer and leukemia group B study 9022. Blood 89: 780–788, 1997

    PubMed  CAS  Google Scholar 

  14. Pui C, Boyett J, Hughes W, et al: Human granulocyte colony stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. N Engl J Med 336: 1781, 1997

    Article  PubMed  CAS  Google Scholar 

  15. Larson R, Dodge R, Linker et al: A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood 92 1556–1564, 1998

    PubMed  CAS  Google Scholar 

  16. Ottmann OG, Hoelzer D, Gracien E, et al: Concomitant granulocyte colony-stimulating factor and induction chemoradiotherapy in adult acute lymphoblastic leukemia: A randomized phase II trial. Blood 86:444, 1995

    PubMed  CAS  Google Scholar 

  17. Bettleheim P, Valent P, Andreef M: Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia. Blood 77: 700–711, 1991

    Google Scholar 

  18. Estey E, Thall P, Kantarjian H, et al: Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSF. Blood 79: 2246–2255, 1992

    PubMed  CAS  Google Scholar 

  19. Zittoun R, Suciu S, Mandelli F, et al: Granulocyte-Macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the european organization for research and treatment of cancer leukemia cooperative group. J Clin Oncol 41: 2150–2159, 1996

    Google Scholar 

  20. Lowenberg B., Suciu S, Archimbaud et al: Using of recombinant granulocyte-macrophage colony-stimulating factor during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia (AML): final report of AML-11, a phase III randomized study of the leukemia cooperative group of european organization for the research and treatment of cancer (EORTC-LCG) and the Dutch elgian Hemato-oncology cooperative group (HOVON). Blood 90: 2952–2961, 1997

    PubMed  CAS  Google Scholar 

  21. Heil G, Chadid L, Hoelzer D: GM-CSF in a double-blind randomized, placebo controlled trial in therapy of sdult patients with de novo acute myeloid leukemia (AML): Leukemia 9: 3–9, 1995

    PubMed  CAS  Google Scholar 

  22. Lowenberg B, Boogaerts M, Daenen S, et al: Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia. J Clin Oncol 15:3496–3506, 1997

    PubMed  CAS  Google Scholar 

  23. Peterson BA, Gerge SL, Bhalla, et al: A phase II trial with or without GM-CSF administered before and during high dose cytarabine in patients with relapsed refractory acute myelogenous leukemia. Proc ASCO 15:504, 1996

    Google Scholar 

  24. Baer M, Bernstein S, Brunetto V: Biological effects of recombinant human granulocyte colony-stimulating factor in patients with untreated acute myeloid leukemia: Blood 87: 1484–1494, 1996

    PubMed  CAS  Google Scholar 

  25. Ohno R, Naoe T, Kanamaru A, et al: A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Blood 83: 2086–2092, 1994

    PubMed  CAS  Google Scholar 

  26. Estey E, Thall P, Beran M, et al: Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML] on outcome of AML-type chemotherapy. Blood 90: 2969–2977, 1997

    PubMed  CAS  Google Scholar 

  27. Ganser A, Volkers B, Greher J, et al: Recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes — a phase I/II trial. Blood 73: 31–37, 1989

    PubMed  CAS  Google Scholar 

  28. Vadhan-Raj S, Keating M, LeMaistre, et al: Effects of recombinant human granulocyte-macrophage colony-stimulatingfactor in patients with myelodysplastic syndromes. N Engl J Med 317: 1545, 1987

    Article  PubMed  CAS  Google Scholar 

  29. Kobayashi Y, Okabe T, Ozawa K, et al: Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor: a primary report. Am J Med 86: 178–182, 1989

    Article  PubMed  CAS  Google Scholar 

  30. Negrin R, Haeuber D, Nagler A, et al: Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. Blood 76: 36–43, 1990

    PubMed  CAS  Google Scholar 

  31. Goy A, Belanger C, Casadevall N: High dose of intravenous recombinant erythropoietin for the treatment of anemia in myelodysplastic syndrome. Brit J Hem atol 84: 232–237, 1993

    Article  CAS  Google Scholar 

  32. Stein R, Abels R, Krantz S: Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes. Blood 78: 1658–1663, 1991

    PubMed  CAS  Google Scholar 

  33. Greenberg P: Treatment of myelodysplastic syndromes with hempoietic growth factors. Sem Oncol 19: 106–114, 1992

    CAS  Google Scholar 

  34. Ganser A, Hoelzer: Clinical use of hematopoietic growth factors in the myelodysplastic syndromes. Sem Hem 33: 186–195, 1996

    CAS  Google Scholar 

  35. You A, Kitagawa S, Okabe T: Recombinant human granulocyte colony-stimulating factor repairs the abnormalities of neutrophils in patients with myelodysplastic syndromes and chronic myelogenous leukemia. Blood 70: 404–411, 1987

    Google Scholar 

  36. Greenberg P, Taylor K, Larson R: Phase II randomized multicenter trial of G-CSF vs, observation for myelodysplastic syndromes (MDS). Blood 82:196a, 1993

    Google Scholar 

  37. Kurzrock R, Talpaz M, Estrov, et al: Phase I study of recombinant human interleukin-3 in patients with bone marrow failure. J Clin Oncol 9:1241–1250, 1991

    PubMed  CAS  Google Scholar 

  38. Ganser A, Lindemann A, Seipelt G, et al: Effect of recombinant human interleukin-3 in patients withnormal hematopoiesis and in patients with bone marrow failure. Blood 76: 666, 1990

    PubMed  CAS  Google Scholar 

  39. Gordon M, Nemunaitis J, Hoffman R, et al: A phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia. Blood 85: 3066–3076, 1995

    PubMed  CAS  Google Scholar 

  40. Tepler I, Elias L, Smith J, et al: A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 87: 3607–3614, 1996

    PubMed  CAS  Google Scholar 

  41. Geissler E, Kabrna S, Stengg I, et al: Recombinant human magakaryocyte growth and development factor augments moblization of hematopoietic progenitor cells post chemotherapy in patients with acute myeloid leukemia. Blood 1997 90:98a

    Google Scholar 

  42. Negrin R, Stein R, Doherty K, et al: Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence of in vitro synergy. Blood 87: 4076–4081, 1996

    PubMed  CAS  Google Scholar 

  43. Negrin RS, Stein R, Vardiman J, et al: Treatment of the anemaia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin. Blood 82: 737–743, 1993

    PubMed  CAS  Google Scholar 

  44. Hellstrom-Lindberg E. Birgegard G, Carlsson M, et al: A combination of granulocyte colony-stimulating factor and erythropoietin may syngergistically improve the anemia in patients with myelodysplastic syndromes. Leuk Lymph 11:221–228, 1993

    Article  CAS  Google Scholar 

  45. Hellstrom-Lindberg E, Ahlgren T, Beguin Y, et al: Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood 92: 68–75, 1998

    PubMed  CAS  Google Scholar 

  46. Estey E: Use of colony-stimulating factors in the treatment of acute myeloid leukemia. Blood 83: 2015–2019, 1994

    PubMed  CAS  Google Scholar 

  47. Geller R: Use of cytokines in the treatment of acute myelocytic leukemia: a critical review. J Clin Oncol 14: 1371–1382, 1996

    PubMed  CAS  Google Scholar 

  48. Schiffer C: Hematopoietic growth factors as adjuncts to the treatment of acute myeloid leukemia. Blood 88:3675–3685, 1996

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Richard M. Stone
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Bone Marrow Transplant Program, Division of Hematology/Oncology, University of Florida College of Medicine, Shands Hospital, Gainesville, FL, 32610, USA

    John R. Wingard M.D. (Professor of Medicine, Director) (Professor of Medicine, Director)

  2. Department of Adult Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, 02115, USA

    George D. Demetri M.D. (Assistant Professor of Medicine) (Assistant Professor of Medicine)

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer Science+Business Media New York

About this chapter

Cite this chapter

Stone, R.M. (1999). Hematopoietic Growth Factors in Acute Leukemia. In: Wingard, J.R., Demetri, G.D. (eds) Clinical Applications of Cytokines and Growth Factors. Developments in Oncology, vol 80. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-5013-6_17

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-5013-6_17

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-7277-6

  • Online ISBN: 978-1-4615-5013-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation